Resources Repository
-
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Technology Assessment | Health Outcomes | Preferences/Values | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Science/Technology | North America | Europe -
GuidelinesPublication 2012Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Task Force-7
This paper discusses how to improve trust in the use of health care models through …
This paper discusses how to improve trust in the use of health care models through validation and transparency. Validation involves face validity (wherein experts evaluate model structure, data sources, assumptions, and results), verification or internal validity (check accuracy of coding), cross validity (comparison of results with other models analyzing same problem), external validity (comparing model results to real-world results), and predictive validity (comparing model results with prospectively observed events). Recommendations are provided for nontechnical description…
Calibration/Validation | Health Outcomes | Costing Methods | Mathematical Models | Health/Medicine -
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
Calibration/Validation | Health Outcomes | Costing Methods | Value of Information | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Dynamic Simulation | Decision Analysis | Infectious Diseases | Health/Medicine -
ReviewPublication 2011Dynamic Microsimulation Models for Health Outcomes: A Review
This review article presents an overview of microsimulation modeling, focusing on the development and application …
This review article presents an overview of microsimulation modeling, focusing on the development and application of these models for health policy questions. Microsimulation models for health outcomes simulate individual event histories associated with key components of a disease process; these simulated life histories can be aggregated to estimate population-level effects of treatment on disease outcomes and the comparative effectiveness of treatments. The authors argue that methodological improvements in modeling approaches have been slowed by the…
Calibration/Validation | Health Outcomes | Microsimulation | Health/Medicine -
Working PaperPublication 2024Economic Evaluation Primer
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence …
Economic evaluation is a powerful tool, encouraging the systematic collection and assessment of the evidence needed to support sound policy decisions. In low- and middle-income countries, where resources are especially scarce and needs are very great, such decisions are exceptionally difficult. In these settings, economic evaluation can be particularly useful in determining how to best improve health and welfare. Typically, cost-effectiveness analysis (CEA) is used to prioritize interventions within the health care sector. This approach…
Health Outcomes | Priority Setting/Ethics | Costing Methods | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Policy/Regulation | Global -
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Health Outcomes | Costing Methods | Evidence Synthesis | Decision Analysis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Policy/Regulation | Health/Medicine | Global | Graduate | Doctoral | Professional -
ReviewPublication 2018Primary & Secondary Prevention Interventions for Cardiovascular Disease in LMIC's
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for …
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for the money, the authors conducted a systematic review, including 50 studies. Included studies were those that reported full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. The majority of the studies were of modelled evaluations, with significant heterogeneity in methods. Most of the economic evaluations evaluated were…
Health Outcomes | Costing Methods | Evidence Synthesis | Chronic Disease/Risk | Health/Medicine | Global -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Health Outcomes | Preferences/Values | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Social Determinants | Policy/Regulation | Economics/Finance | Health/Medicine | Global | Critical Thinking/Analysis -
GuidelinesWeb Portal 2017iDSI Reference Case for Economic Evaluation
This is a reference case which gives 12 principles to guide the planning, conduct and …
This is a reference case which gives 12 principles to guide the planning, conduct and reporting of health economic evaluations in low- and middle-income countries (LMICs). The International Decision Support Group (iDSI) is a network of health, policy and economic experts. It builds on the approaches of the National Institute for Health and Care Excellence (NICE) in the UK, the Health Intervention and Technology Assessment Program (HITAP) in Thailand and the World Health Organization. iDSI…
Health Outcomes | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Health/Medicine | Global